anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The title low-toxicity curative agent aht is obtained by extracting sufficiently air-oxidized acidic sulfate soil with water, concentrating the extract and dying to form powdery products, thus showing the prevention of bacterial infection on the injured skin and acceleration of curative action. CONSTITUTION:An acidic sulfate soil is sufficiently oxidized with air and extracted with water. The extracted is concentrated to dryness and the resultant powder is used as an active ingredient of the objective agent. The resultant powder inhibits the propagation of Pseudomonas areuginosa or diseasecausative Escherichea coil to prevent bacterial infection in the injured skin and promote curing action. The effective does depends on the degree of damage of the skin, but it is desirably more than 1mg/cm<2> in case of direct application to the injured skin. It is given one to several times during the treating period. It has very low toxicity and high safety.
Laparoscopic radical hysterectomy with pelvic lymphadenectomy are performed with standard laparoscopy technology. A 10 mm port is inserted at the umbilicus for the telescope. Once pneumoperitoneum (12 mmHg) is achieved, intra-abdominal visualization will be obtained with a 0° high-definition telescope. Two additional 5 mm ports are placed under direct visualization. One more 5 mm trocar is inserted in the right mid abdomen at the level of the umbilicus. The instruments used include bipolar grasper, monopolar scissors, monopolar hook, various graspers and a suction irrigation system.
Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone.

Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert in vivo. No differences were found in the pharmacologic activity between the two enantiomers. The structural formula is as shown:

Pioglitazone hydrochloride is an odorless white crystalline powder that has a molecular formula of C19H20N2O3S•HCl and a molecular weight of 392.90 daltons. It is soluble in N,N-­dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water, and insoluble in ether.

Pioglitazone Tablets USP are available as a tablet for oral administration containing 15 mg, 30 mg, or 45 mg of pioglitazone (as the base) formulated with the following excipients: carboxymethylcellulose calcium, hydroxypropyl cellulose, lactose monohydrate, and magnesium stearate.
This study is a double-blind, randomized, placebo-controlled, parallel design trial enrolling 80 patients (2x40) with Type 1 diabetes and microalbuminuria. Patients will be randomized to either 200 mg Alagebrium twice daily or placebo for a period of 24 weeks after an 8 week run-in period. There will be a 8 week run-out period. All patients will receive ramipril during the entire study period. Efficacy measurements will be performed at baseline, at 12 weeks and at the end of the study. Measurements for albumin:creatinine ratio(mg/g), plasma renin level, collagen markers, AGE related markers and 24 hour blood pressure measurements will also be determined. A total of 9 visits will be performed during the entire study.
Intervention group participants receive 1 Family Spirit Nurture lesson taught by Family Health Coaches. Mothers will receive the lesson within 1-2 weeks of completing the 4-year Follow-up Assessment. The lesson focuses on age-appropriate parental feeding practices, including snack routines, avoidance of SSBs and promotion of water consumption. The lesson is highly visual and interactive, and incorporates cultural teachings related to child feeding and nutrition that support aims. The Family Health Coaches also provide social support and will facilitate referrals to community resources.
Participants in the experimental group participated in three 60-minute training sessions each week for 12 weeks. One of the session was group training. The other two session were individual training. In the group training session, the participants participate in the video aerobic exercise; in the individual sessions, the participants play action and resistive action video games: Fitness Boxing 2 and Adventure Ring-Fit. All participants in the experimental group wore a hear rate monitoring watch so that the researchers make sure that medium level of physical activities was achieved in each session. The participants underwent pre-, mid- and post-training measures of the outcome parameters which includes body weight, body mass index, basal metabolic rate, skeletal muscle rate, body fat percentage, flexibility, balance and agility.
The sham intervention will take place for up to 45 minutes per day, 5 days per week for 6 weeks. The device will be in 'sham' mode (attached to the earlobe). The stimulation device will be worn whilst completing computer-based Speech and Language Therapy.
71 patients with cleft palate received surgery were divided into 3 groups. Group 1: patients who received Langenbeck surgery without specific restoration of levator veli palatini or tensor veli palatini. Group 2: patients who received palate surgery with special levator veli palatini restoration. Group 3: patients who received palate surgery with modified tensor veli palatini restoration. The conductive auditory brainstem response and 226 Hz tympanometry were used to test the audiological and otological status of the three groups. Preoperative and postoperative results were compared intragroup and intergroup.
1. A composition for use in ophthalmologic surgery comprising a viscoelastic polymer and an agent selected from the group consisting of miotic agents and mydriatic agents. 2. The composition of claim 1, wherein the viscoelastic polymer is hyaluronic acid and the agent is atropine. 3. The composition of claim 1, wherein the viscoelastic polymer is hyaluronic acid and the agent is pilocarpine. 4. The composition of claim l, wherein the viscoelastic polymer is hyaluronic acid and the agent is phenylephrine. 5. The composition of claim 1, wherein the viscoelastic polymer is hyaluronic acid and the agent is isopilocarpine. 6. The composition of claim 1, wherein the viscoelastic polymer and the agent are comprised in a complex, wherein the complex is acetylcholine hyaluronate. 7. The composition of claim I comprising an anionic viscoelastic polymer and a cationic agent selected from the group consisting of miotic agents and mydriatic agents. 8. The composition of claim 7, wherein the viscoelastic polymer is sodium hyaluronate and the agent is atropine sulfate. 9. The composition of claim 7, wherein the viscoelastic polymer is chondroitin sulfate and the agent is pilocarpine hydrochloride. 10. The composition of claim 7, wherein the viscoelastic polymer is sodium hyaluronate and the agent is phenylephrine hydrochloride. 11. The composition of claim 7, wherein the viscoelastic polymer is sodium hyaluronate and the agent is acetylcholine chloride. 12. The composition of claim 7, wherein the viscoelastic polymer is sodium hyaluronate and the agent is pilocarpine hydrochloride. 13. The composition of claim 7, wherein the viscoelastic polymer is sodium hyaluronate and the agent is isopilocarpine hydrochloride. 14. A medicament composition comprising biodegradable micro capsules which comprise an agent selected from the group consisting of miotic agents and mydriatic agents. 15. The medicament composition according to claim 14 wherein the microcapsules are constructed of polylactide. 16. The medicament composition according to claim 14 where the microcapsules are constructed of co-poly(lactideglycolide). 17. The medicament composition according to claim 14 which further comprises a viscoelastic polymer. 18. The medicament composition comprising soluble copolymer micelles comprising an agent selected from the group consisting of miotic agents and mydriatic agents, wherein the micelles comprise a hydrophilic and a hydrophobic portion, and the agent is absorbed into the hydrophobia portion of the copolvmer micelle. 19. The composition according to claim 18, wherein the micelle comprises ethylene oxide-propylene oxide-ethylene oxide block copolymer. 20. The composition according to claim 19, wherein the micelle further comprises phenylephrine. 21. The composition according to claim 18, which further comprises a viscoelastic polymer. 22. A method of maintaining the structural integrity of the anterior chamber of the eye during surgery whilst concurrently maintaining the desired pupil size, comprising administering the composition of any one of claims 1 or 21.
The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and its underlying neural mechanisms and whether oxytocin has similar effects on them or not. A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A modified inequity decision-making task starts 45 minutes after treatment with behavioral (fairness rating, preference rating and the choice rate of unequal option) and fMRI data being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the task.
Arm5 (Pathological classification: Mucinous Ovarian cancer, Ovarian carcinosarcoma; Biomarkers: \<3 CD8+ TILs count: Bevacizumab 7.5mg/kg IV. D1, 15 + Nab-paclitaxel 100mg / m2 IV. D1, 8, 15 (Q4w).
Altered mechanotransduction has been proposed as a putative mechanism for disease pathophysiology, yet evidence remains scarce. Here we introduce a concept we call single cell immuno-mechanical modulation, which links immunology, integrin biology, cellular mechanics, and disease pathophysiology and symptomology. Using a micropatterned hydrogel-laden coverslip compatible with standard fluorescence microscopy, we conduct a clinical mechanobiology study, specifically focusing on immune thrombocytopenia (ITP), an autoantibody-mediated platelet disorder that currently lacks a reliable biomarker for bleeding risk. We discover that in pediatric ITP patients (n = 53), low single platelet contraction force alone is a "physics-based" biomarker of bleeding (92.3% sensitivity, 90% specificity). Mechanistically, autoantibodies and monoclonal antibodies drive increases and decreases of cell force by stabilizing integrins in different conformations depending on the targeted epitope. Hence, immuno-mechanical modulation demonstrates how antibodies may pathologically alter mechanotransduction to cause clinical symptoms and this phenomenon can be leveraged to control cellular mechanics for research, diagnostic, and therapeutic purposes.
FIELD: molecular biology, immunology. SUBSTANCE: invention relates to methods for detection of inductors and inhibitors of proteolytic antibodies, compositions based on thereof and their application. Invention involves covalently bound antigenic analogue of structural formula: X1-Y-E-X2 wherein X1 and X2 are peptide sequences consisting of 3-10 amino acids of peptide epitope associated with the disease; Y is a positively charged amino acid residue; E is an electrophilic reaction center. Invention relates also to method for stimulation of antibodies producing with catalytic activity, catalytic antibody, to method for passive immunization of patient, to method for active immunization of patient with respect to bacterial infection, to pharmaceutical composition used for treatment of pathological state. The advantage of invention involves the development of compositions and methods for stimulation of catalytic antibodies producing. EFFECT: improved detection method, valuable properties compositions. 22 cl, 19 dwg, 5 ex
INTRODUCTION: Femoral neck shortening is a common phenomenon following osteosynthesis for femoral neck fractures, which was shown to have a negative effect on hip function. There is paucity of literature on the effect of shortening on the ipsilateral limb mechanical axis and knee coronal alignment. We hypothesized that postoperative femoral neck shortening can alter the limb's mechanical axis into valgus.
METHODS: Of 583 patients screened, 13 patients with severe neck shortening (< 10 mm) following femoral neck fracture fixation, were found eligible and agreed to participate. A full-length lower limb radiographs were obtained and radiographic parameters (offset, neck-shaft angle, HKA, mLPFA, mDLFA, mMPTFA, MAD, MAD-r) as well as functional scores were obtained.
RESULTS: Statistically significant differences in mechanical axis deviation ratio (MAD-r) were found between the ipsilateral and the contralateral extremities (0.41 ± 0.16 versus 0.55 ± 0.11, p = 0.03). A correlation between femoral neck length differences and MAD was not statistically significant although a tendency towards lateral deviation of the mechanical axis was noted (r = - 0.5, p = 0.077). A negative correlation was found between a greater difference in the femoral neck length and the SF12 score, both in the physical and the mental parts (r = - 0.69, p = 0.008; r = - 0.58, p = 0.035, respectively).
CONCLUSION: We found a more lateralized mechanical axis in limbs that demonstrated post-operative ipsilateral femoral neck severe shortening. These findings may provide a possible explanation and rationale for knee pain and perhaps for the development of knee osteoarthritis as a sequalae of femoral neck shortening. Further investigation and larger cohort, long-term studies are needed to further explore this hypothesis.
1357737 Sustained release compositions ETABS ARPIC SA 23 Sept 1971 [9 Oct 1970] 48167/70 Heading A5B Sustained release pharmaceutical compositions comprising a matrix formed from acetyl salicylic acid (ASA) or a pharmaceutically acceptable salt (e.g. Na or Ca salts) or complex thereof (e.g. complexes with glycine or urea), or physiologically acceptable polysiloxane and a water-insoluble cellulose ether or ester may be prepared by combining ASA (or the salt or complex thereof), a polysiloxane and a waterinsoluble cellulose ether or ester in a liquid medium and removing the liquid medium. The polysiloxane may be a dialkyl polysiloxane such as dimethylpolysiloxane and the cellulose derivative is preferably ethyl cellulose or cellulose acetobutyrate. The compositions may be in the form of dosage units, such as capsules, tablets, coated tablets, dragees, sachets, powders or granules, which may also contain a further amount of ASA in addition to the ASA incorporated in the matrix. The liquid medium may comprise an aliphatic halohydrocarbon such as methylene chloride, chloroform or carbon tetrachloride and/or an aromatic hydrocarbon such as benzene or toluene. A solution of the polysiloxane in toluene may be admixed with a solution of the cellulose ether or ester in toluene and methylene chloride in the presence of ASA in solid form.
Randomized patients in this arm will receive single oral dose of LJN452 daily for 14 days. There will be a washout period between 7 to 28 days followed by single oral dose of placebo daily for 14 days.
BACKGROUND: Lower limb amputation can lead to psychological problems.There is a lack of data to evaluate the psychological problems and associated factors in lower limb amputees.
AIM: Prevalence and factors associated with psychological disorder and phantom limb pain in lower limb amputees METHODS: It was a cross-sectional study with a consecutive sampling technique. Patients were assessed on the Hospital Anxiety and Depression Scale (HADS) for the presence of depression and anxiety disorder. DSM-5 diagnostic criteria for substance use disorder were used, andphantom limb pain was diagnosed as defined by Pare.
RESULTS: 103 patients were included in the present study with a mean age of37.7 ± 14.5 yrs. The majorityof patients were males (87.4 %), married (69.9 %), on paid employment (95.1 %), and were of middle socioeconomic status (83.5 %). Most of the patients presented with roadside accident injuries (83.5 %)and had below-knee amputation (58.3 %). As per DSM-5, 38.8 % had a substance use disorder, out of which 35.9 % and 24.3 % had alcohol and tobacco use disorders, respectively. On HADS, 48.5 % had a presence of depressive disorder, and 30.1 % had anxiety disorder. The majority of patients (97.1 %) had phantom limb pain. Those from rural areas reported significantly more frequency of anxiety (x2-5.501; p-0.019) and depressive disorder (x2-7.009; p-0.008). Lower incomehad a significant positive association with depression (r-0.228; p-0.021) and phantom limb pain (U-22.500; p-0.008).
CONCLUSION: The prevalence of psychiatric morbidity in lower-limb amputeeswas very high. The most common psychological morbidity was depression,followed by anxiety disorder and substance use disorders.Our findings reflect that we would benefit by including mental health professionals asintegral members of the multidisciplinary team to do an early psychological assessment and intervention, which would help prevent psychological illnesses and improve quality of life.
Although polyploid plants have lower stomatal density than their diploid counterparts, the molecular mechanisms underlying this difference remain elusive. Here, we constructed a network based on the triploid poplar transcriptome data and triple-gene mutual interaction algorithm and found that PpnMYC2 was related to stomatal development-related genes PpnEPF2, PpnEPFL4, and PpnEPFL9. The interactions between PpnMYC2 and PagJAZs were experimentally validated. PpnMYC2-overexpressing poplar and Arabidopsis thaliana had reduced stomatal density. Poplar overexpressing PpnMYC2 had higher water use efficiency and drought resistance. RNA-sequencing data of poplars overexpressing PpnMYC2 showed that PpnMYC2 promotes the expression of stomatal density inhibitors PagEPF2 and PagEPFL4 and inhibits the expression of the stomatal density-positive regulator PagEPFL9. Yeast one-hybrid system, electrophoretic mobility shift assay, ChIP-qPCR, and dual-luciferase assay were employed to substantiate that PpnMYC2 directly regulated PagEPF2, PagEPFL4, and PagEPFL9. PpnMYC2, PpnEPF2, and PpnEPFL4 were significantly upregulated, whereas PpnEPFL9 was downregulated during stomatal formation in triploid poplar. Our results are of great significance for revealing the regulation mechanism of plant stomatal occurrence and polyploid stomatal density, as well as reducing stomatal density and improving plant water use efficiency by overexpressing MYC2.
<P>PROBLEM TO BE SOLVED: To enhance a therapeutic effect of a treating agent in the treatment of abnormal tissue of an animal by reinforcing the permeability of vascular structure of the abnormal tissue.  <P>SOLUTION: A photo-sensitive agent is a porphyrin derivative photo-sensitive agent for treating the abnormal tissue of the animal. The treatment is a process of introducing the photo-sensitive agent into the blood stream of the animal. The photo-sensitive agent exhibits its action through a process of having better selectivity to the abnormal tissue than that to normal tissue for obtaining the abnormal tissue containing the photo-sensitive agent, and a process of exposing the abnormal tissue containing the photo-sensitive agent to light for activating the photo-sensitive agent and reinforcing the permeability of the vascular structure in the abnormal tissue. The treating agent reaches the abnormal tissue by passing through the vascular structure the permeability of which is reinforced, and affects the abnormal tissue.  <P>COPYRIGHT: (C)2004,JPO
Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically- altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and/or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products. ® KIPO & WIPO 2007
Patients in the arm will be given an injection of 0.9% sodium chloride (normal saline) solution at baseline (day 0). A plastic 1 mL syringe will be prefilled by the study pharmacy. Each syringe will contain 0.5 mL (0.45 mL to match the volume of the Interferon plus 0.05 mL overfill) to allow for needle priming by the unblinded study nurse. Patients will be administered a second dose of placebo on day 5.
A restoration is made using an alloy of approximately 80 percent Ni - 20 percent Cr employing conventional casting techniques heretofore used with precious metals. After the casting has been cleaned it is heated under vacuum commencing at 1,400*- 1,500*F. and increasing gradually to approximately 1,950*F. The vacuum is released and the casting cooled -- a grayish blue colored compound forming on the surface. Porosities and casting defects may be conveniently repaired using ceramic gold paste. The metal may be soldered, to other metal members, whether of the same alloy or gold or any other conventional metal. Porcelain is then applied, again using conventional techniques. The product is characterized by the very good bond of porcelain to metal, extreme dimensional accuracy and relatively low cost of metal.
No intervention. Measurements of plasma marine n-3 polyunsaturated fatty acids levels, indicating intake of fish and seafood.
Thermoforming was applied to the lower abdomen by the subjects themselves when the dysmenorrhea pain was at its peak. The subjects were instructed on the application of the thermophores. Thermoforming was applied wrapped in towels in order to shield the subjects from the effects of direct heat. In a study, heat packs that had a temperature of 38.9 °C were used for treatment of dysmenorrhea. In this study, the temperature of the water used in the thermoforming process was 45 °C. Considering the risk of the thermophores cooling down and the shielding provided by the towels, the water temperature was kept higher compared to those in other studies. The temperature of the water was measured using a liquid thermometer. Heat treatment was applied for 20 minutes without interruptions.